374 related articles for article (PubMed ID: 28530668)
1. Radioimmunotherapy-augmented BEAM chemotherapy vs BEAM alone as the high-dose regimen for autologous stem cell transplantation (ASCT) in relapsed follicular lymphoma (FL): a retrospective study of the EBMT Lymphoma Working Party.
Bento L; Boumendil A; Finel H; Le Gouill S; Amorim S; Monjanel H; Bouabdallah R; Bay JO; Nicolas-Virelizier E; McQuaker G; Rossi G; Johnson R; Huynh A; Ceballos P; Rambaldi A; Bachy E; Malladi R; Orchard K; Pohlreich D; Tilly H; Bonifazi F; Poiré X; Guilhot F; Haenel A; Crawley C; Metzner B; Gribben J; Russell NH; Damaj G; Thomson K; Dreger P; Montoto S
Bone Marrow Transplant; 2017 Aug; 52(8):1120-1125. PubMed ID: 28530668
[TBL] [Abstract][Full Text] [Related]
2. Prognostic differences between carmustine, etoposide, cytarabine and melphalan (BEAM) and carmustine, etoposide, cytarabine, melphalan and fludarabine (BEAMF) regimens before autologous stem cell transplantation plus chimeric antigen receptor T therapy in patients with refractory/relapsed B-cell non-Hodgkin-lymphoma.
Xin X; Lin L; Yang Y; Wang N; Wang J; Xu J; Wei J; Huang L; Zheng M; Xiao Y; Meng F; Cao Y; Zhu X; Zhang Y
Cytotherapy; 2024 May; 26(5):456-465. PubMed ID: 38385909
[TBL] [Abstract][Full Text] [Related]
3. Yttrium-90 ibritumomab tiuxetan (Zevalin) followed by BEAM (Z-BEAM) conditioning regimen and autologous stem cell transplantation (ASCT) in relapsed or refractory high-risk B-cell non-Hodgkin lymphoma (NHL): a single institution Italian experience.
Ciochetto C; Botto B; Passera R; Bellò M; Benevolo G; Boccomini C; Castellino A; Chiappella A; Freilone R; Nicolosi M; Orsucci L; Pecoraro C; Pregno P; Bisi G; Vitolo U
Ann Hematol; 2018 Sep; 97(9):1619-1626. PubMed ID: 29663029
[TBL] [Abstract][Full Text] [Related]
4. Comparison of 2 Carmustine-Containing Regimens in the Rituximab Era: Excellent Outcomes Even in Poor-Risk Patients.
Caimi PF; William BM; Silva Rondon CH; Fu P; Cooper BW; Campagnaro EL; Gerson SL; Reese-Koc J; Fox R; Creger RJ; de Lima M; Lazarus HM
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1926-31. PubMed ID: 26087475
[TBL] [Abstract][Full Text] [Related]
5. Iodine-131 rituximab radioimmunotherapy with BEAM conditioning and autologous stem cell transplant salvage therapy for relapsed/refractory aggressive non-Hodgkin lymphoma.
Kruger PC; Cooney JP; Turner JH
Cancer Biother Radiopharm; 2012 Nov; 27(9):552-60. PubMed ID: 23062193
[TBL] [Abstract][Full Text] [Related]
6.
Conlon KC; Sportes C; Brechbiel MW; Fowler DH; Gress R; Miljkovic MD; Chen CC; Whatley MA; Bryant BR; Corcoran EM; Kurdziel KA; Pittaluga S; Paik CH; Lee JH; Fleisher TA; Carrasquillo JA; Waldmann TA
Cancer Biother Radiopharm; 2020 May; 35(4):249-261. PubMed ID: 32275165
[No Abstract] [Full Text] [Related]
7. High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults.
Schaaf M; Reiser M; Borchmann P; Engert A; Skoetz N
Cochrane Database Syst Rev; 2012 Jan; 1():CD007678. PubMed ID: 22258971
[TBL] [Abstract][Full Text] [Related]
8. (90)Y ibritumomab tiuxetan (Zevalin) combined with BEAM (Z -BEAM) conditioning regimen plus autologous stem cell transplantation in relapsed or refractory low-grade CD20-positive B-cell lymphoma. A GELA phase II prospective study.
Decaudin D; Mounier N; Tilly H; Ribrag V; Ghesquières H; Bouabdallah K; Morschhauser F; Coiffier B; Le Gouill S; Bologna S; Delarue R; Huynh A; Bosly A; Brière J; Gisselbrecht C
Clin Lymphoma Myeloma Leuk; 2011 Apr; 11(2):212-8. PubMed ID: 21575926
[TBL] [Abstract][Full Text] [Related]
9. Updated Results of Rituximab Pre- and Post-BEAM with or without
Chahoud J; Sui D; Erwin WD; Gulbis AM; Korbling M; Zhang M; Ahmed S; Alatrash G; Anderlini P; Ciurea SO; Oran B; Fayad LE; Bassett RL; Jabbour EJ; Medeiros LJ; Macapinlac HA; Young KH; Khouri IF
Clin Cancer Res; 2018 May; 24(10):2304-2311. PubMed ID: 29476021
[No Abstract] [Full Text] [Related]
10. A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma.
Shimoni A; Avivi I; Rowe JM; Yeshurun M; Levi I; Or R; Patachenko P; Avigdor A; Zwas T; Nagler A
Cancer; 2012 Oct; 118(19):4706-14. PubMed ID: 22252613
[TBL] [Abstract][Full Text] [Related]
11. Clinical characteristics and outcomes of relapsed follicular lymphoma after autologous stem cell transplantation in the rituximab era.
Sesques P; Bourcier J; Golfier C; Lebras L; Nicolas-Virelizier E; Hacini M; Perrin MC; Voillat L; Bachy E; Traverse-Glehen A; Moreau A; Martin L; Ramla S; Casasnovas O; Le Gouill S; Salles G; Ghesquières H
Hematol Oncol; 2020 Apr; 38(2):137-145. PubMed ID: 31953963
[TBL] [Abstract][Full Text] [Related]
12. Outcome of BEAM-autologous and BEAM-alemtuzumab allogeneic transplantation in relapsed advanced stage follicular lymphoma.
Ingram W; Devereux S; Das-Gupta EP; Russell NH; Haynes AP; Byrne JL; Shaw BE; McMillan A; Gonzalez J; Ho A; Mufti GJ; Pagliuca A
Br J Haematol; 2008 Apr; 141(2):235-43. PubMed ID: 18318762
[TBL] [Abstract][Full Text] [Related]
13. BEAM Conditioning Regimen Has Higher Toxicity Compared With High-Dose Melphalan for Salvage Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.
Veeraputhiran M; Jain T; Deol A; Ayash L; Kim S; Dyson G; Bhutani D; Lum LG; Ratanatharathorn V; Uberti JP; Abidi MH
Clin Lymphoma Myeloma Leuk; 2015 Sep; 15(9):531-5. PubMed ID: 26166312
[TBL] [Abstract][Full Text] [Related]
14. A 15-year analysis of early and late autologous hematopoietic stem cell transplant in relapsed, aggressive, transformed, and nontransformed follicular lymphoma.
Sabloff M; Atkins HL; Bence-Bruckler I; Bredeson C; Fergusson D; Genest P; Hopkins H; Hutton B; Mcdiarmid S; Huebsch LB
Biol Blood Marrow Transplant; 2007 Aug; 13(8):956-64. PubMed ID: 17640600
[TBL] [Abstract][Full Text] [Related]
15. Phase III randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the BMT CTN 0401 trial.
Vose JM; Carter S; Burns LJ; Ayala E; Press OW; Moskowitz CH; Stadtmauer EA; Mineshi S; Ambinder R; Fenske T; Horowitz M; Fisher R; Tomblyn M
J Clin Oncol; 2013 May; 31(13):1662-8. PubMed ID: 23478060
[TBL] [Abstract][Full Text] [Related]
16. A Comparison of the Conditioning Regimens BEAM and FEAM for Autologous Hematopoietic Stem Cell Transplantation in Lymphoma: An Observational Study on 1038 Patients From Fondazione Italiana Linfomi.
Olivieri J; Mosna F; Pelosini M; Fama A; Rattotti S; Giannoccaro M; Carli G; Tisi MC; Ferrero S; Sgherza N; Mazzone AM; Marino D; Calimeri T; Loseto G; Saraceni F; Tomei G; Sica S; Perali G; Codeluppi K; Billio A; Olivieri A; Orciuolo E; Matera R; Stefani PM; Borghero C; Ghione P; Cascavilla N; Lanza F; Chiusolo P; Finotto S; Federici I; Gherlinzoni F; Centurioni R; Fanin R; Zaja F;
Biol Blood Marrow Transplant; 2018 Sep; 24(9):1814-1822. PubMed ID: 29857196
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes.
Flowers CR; Costa LJ; Pasquini MC; Le-Rademacher J; Lill M; Shore TB; Vaughan W; Craig M; Freytes CO; Shea TC; Horwitz ME; Fay JW; Mineishi S; Rondelli D; Mason J; Braunschweig I; Ai W; Yeh RF; Rodriguez TE; Flinn I; Comeau T; Yeager AM; Pulsipher MA; Bence-Bruckler I; Laneuville P; Bierman P; Chen AI; Kato K; Wang Y; Xu C; Smith AJ; Waller EK
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1197-1205. PubMed ID: 27040394
[TBL] [Abstract][Full Text] [Related]
18. Autologous stem cell transplantation for follicular lymphoma: no benefit for early transplant?
Seyfarth B; Kuse R; Sonnen R; Glass B; Schmitz N; Dreger P
Ann Hematol; 2001 Jul; 80(7):398-405. PubMed ID: 11529465
[TBL] [Abstract][Full Text] [Related]
19. A randomized phase II study of standard-dose versus high-dose rituximab with BEAM in autologous stem cell transplantation for relapsed aggressive B-cell non-hodgkin lymphomas: long term results.
Srour SA; Li S; Popat UR; Qazilbash MH; Lozano-Cerrada S; Maadani F; Alousi A; Kebriaei P; Anderlini P; Nieto Y; Jones R; Shpall E; Champlin RE; Hosing C
Br J Haematol; 2017 Aug; 178(4):561-570. PubMed ID: 28485023
[TBL] [Abstract][Full Text] [Related]
20. Tandem high-dose therapy in relapsed and refractory B-cell lymphoma: results of a prospective phase II trial of myeloablative chemotherapy, followed by escalated radioimmunotherapy with (131)I-anti-CD20 antibody and stem cell rescue.
Hohloch K; Sahlmann CO; Lakhani VJ; Wulf G; Glass B; Hasenkamp J; Meller J; Riggert J; Trümper L; Griesinger F
Ann Hematol; 2011 Nov; 90(11):1307-15. PubMed ID: 21360108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]